FI104655B - Diagnostiskt förfarande - Google Patents

Diagnostiskt förfarande Download PDF

Info

Publication number
FI104655B
FI104655B FI922666A FI922666A FI104655B FI 104655 B FI104655 B FI 104655B FI 922666 A FI922666 A FI 922666A FI 922666 A FI922666 A FI 922666A FI 104655 B FI104655 B FI 104655B
Authority
FI
Finland
Prior art keywords
cells
prosome
proteins
directed against
leu
Prior art date
Application number
FI922666A
Other languages
English (en)
Finnish (fi)
Other versions
FI922666A0 (fi
Inventor
Klaus Scherrer
Jean Paul Bureau
Faycal Bey
Original Assignee
Pro Soma Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Soma Sarl filed Critical Pro Soma Sarl
Publication of FI922666A0 publication Critical patent/FI922666A0/fi
Application granted granted Critical
Publication of FI104655B publication Critical patent/FI104655B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrotherapy Devices (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Claims (10)

1. Förfarande för att diagnostisera human immunbristsvirusinfektion hos en patient, k ä n n e- 5 tecknat av att a) man undersöker ur patienten tagen kroppsvätska för proteiner som förekommer pA cellytor under användning av stämplade antikroppar, stämplade antikroppsfragment eller blandningar av dessa, varvid nämnda proteiner 10 reagerar med antikroppar som är riktade mot prosomproteiner eller en prosomliknande partikel, för kvantitativ bestämning av antalet eller procentandelen sädana celler pA vilkas ytor detta protein förekommer, och 15 b) det sä erhallna antalet eller den sA erhAllna procentandelen jämförs med en standard som erhallits fran en person som inte är infekterad med det humana immunbristviruset.
2. Förfarande enligt patentkrav 1, k ä n n e- 20 tecknat av att antikropparna och antikropps-fragmenten är antikroppar riktade mot prosomproteiner p23K, p25K, p27K, p29K (p28K, p33K), p30/33K och p31K eller den prosomliknande partikelns p21K-protein, eller härstammar l frAn dessa antikroppar. 25
3. Förfarande enligt patentkrav 2, k ä n n e- tecknat av att cellerna är patientens B4-celler och antikroppen är en mot p23K riktad monoklonal antikropp.
4. Förfarande enligt patentkrav 2, k ä n n e- tecknat av att cellerna är patientens T4-celler och 30 antikroppen är en mot p27K riktad antikropp, som har lyfts upp mot det i sekvens nr 2 identifierade proteinet eller dess antigena fragment.
5. Förfarande enligt patentkrav 1, k ä n n e- tecknat av att antikroppen är en antikropp som har 26 1 0 4 6 5 5 lyfts upp mot det i sekvens nr 4 identifierade proteinet eller dess antigena fragment.
6. Förfarande enligt patentkrav 1, k ä n n e- tecknat av att cellerna är patientens T8-celler och 5 antikropparna är monoklonala antikroppar, som är riktade mot nägot av prosomproteinerna p23K, p25Kf p27K, p29K (p28K, p33K), p30/33K och p31K eller mot den prosomliknande partikelns p21K-protein.
7. Förfarande enligt patentkrav 1, k ä n n e- 10 tecknat av att cellerna är patientens naturliga mördarceller och antikropparna är monoklonala antikroppar, som är riktade mot nägot av prosomproteinerna p25K, p29K (p28K, p33K) , p30/33K och p31K eller mot den prosomliknande partikelns p21K-protein. 15
8. Förfarande enligt patentkrav 1, k ä n n e- tecknat av att cellerna är patientens T3-lymf ocyter och antikropparna är antikroppar som är riktade mot nägot av prosomproteinerna p23K, p25K, p29K (p28K, p33K), p30/33K och p31K eller mot den prosomliknande partikelns 20 p21K-protein.
9. In vitro-förfarande för diagnostisering av humant immunbristvirusinfektion, kännetecknat av att celler, som är B4-celler, T4-celler, T8-celler, naturliga mördarceller, T3-lymfocyter eller blandningar " 25 av dessa celler, identifieras eller isoleras under användning av mot dessa celler riktade antikroppar, pä detta sätt isolerade celler inkuberas under användning av mot prosomproteiner eller en prosomliknande partikel riktade stämplade monoklonala antikroppar, och 30 proteiner pä cellytan undersöks med hjälp av m'. dessa.
10. Diagnostisk testförpackning som lämpar sig för * diagnos av human immunbristvirusinfektion, k ä n n e-tecknad av att den omfattar antikroppar som är riktade 35 mot B4-celler, T4-celler, T8-celler, naturliga "1 md 1046.55 mördarceller, T3-lymfocyter eller blandningar av dessa celler och anslutna med en fast yta, och en diagnos-tisk vätska, som innehäller mot prosomproteiner eller en prosomliknande partikel riktade stämplade antikroppar. * · t
FI922666A 1990-10-11 1992-06-09 Diagnostiskt förfarande FI104655B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP90402838 1990-10-11
EP90402838 1990-10-11
EP9101945 1991-10-10
PCT/EP1991/001945 WO1992007269A1 (en) 1990-10-11 1991-10-10 Diagnostic method

Publications (2)

Publication Number Publication Date
FI922666A0 FI922666A0 (fi) 1992-06-09
FI104655B true FI104655B (sv) 2000-03-15

Family

ID=8205759

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922666A FI104655B (sv) 1990-10-11 1992-06-09 Diagnostiskt förfarande

Country Status (9)

Country Link
US (1) US5635345A (sv)
EP (1) EP0504371B1 (sv)
JP (1) JPH05503712A (sv)
AT (1) ATE146596T1 (sv)
AU (1) AU652193B2 (sv)
CA (1) CA2069424A1 (sv)
DE (1) DE69123723T2 (sv)
FI (1) FI104655B (sv)
WO (1) WO1992007269A1 (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923679B (en) * 1991-06-21 1993-01-27 Pro Soma Sarl Diagnostic method
US6544750B1 (en) 1999-08-17 2003-04-08 Thromgen, Inc. Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586814A1 (fr) * 1985-08-30 1987-03-06 Centre Nat Rech Scient Anticorps monoclonaux anti-proteines p 27 k et p 31 k de prosomes et leur application a titre de reactifs de diagnostic et/ou d'identification de cellules
JPH01309686A (ja) * 1988-06-08 1989-12-14 Otsuka Pharmaceut Co Ltd 多機能プロテアーゼ

Also Published As

Publication number Publication date
EP0504371B1 (en) 1996-12-18
JPH05503712A (ja) 1993-06-17
EP0504371A1 (en) 1992-09-23
AU8741691A (en) 1992-05-20
ATE146596T1 (de) 1997-01-15
WO1992007269A1 (en) 1992-04-30
US5635345A (en) 1997-06-03
CA2069424A1 (en) 1992-04-12
AU652193B2 (en) 1994-08-18
DE69123723D1 (de) 1997-01-30
DE69123723T2 (de) 1997-04-17
FI922666A0 (fi) 1992-06-09

Similar Documents

Publication Publication Date Title
CN111217920B (zh) 新冠病毒n-s优势表位融合蛋白、制备方法、应用，及表达蛋白、微生物、应用，试剂盒
EP0199438B1 (en) Htlv iii polypeptides
Chambers et al. Isolation and analysis of cDNA clones expressing human lupus La antigen.
US6406841B1 (en) Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides
JP2574224B2 (ja) ペプチド
WO1995001457A9 (en) Htlv-iinra compositions and assays for detecting htlv infection
FI104655B (sv) Diagnostiskt förfarande
JP2858467B2 (ja) 分子クローニングにより得られたランゲルハンス島細胞の抗原
CA2499926A1 (en) Antibody against von willebrand factor cleaving enzyme and assay system using the same
CN117700534B (zh) 一种抗猴痘病毒a35r蛋白的抗体及其应用
CN116789834B (zh) 一种抗人cd56工程抗体及应用
EP1242450B1 (en) Organ transplant rejection and associated conditions
JP2007145775A (ja) ノロウイルスｇｉの高感度検出方法
EP0908466B1 (en) Anti-human lect2 antibody, cells producing the same, and method and kit for assaying the same
CA2387576C (en) Immuno-interactive fragments of the .alpha.c subunit of inhibin
EP0506914B1 (en) Method for the diagnosis of hiv infections
AU782490B2 (en) Immuno-interactive fragments of the alphaC subunit of inhibin
US20040234537A1 (en) Carcinoma-related peptides
JP2000002709A (ja) 白血病の検出方法及び検出キット
CN117434275A (zh) 一种嵌合抗原受体检测试剂及其制备与应用
CN117186221A (zh) 大内皮素-1特异性抗体及其制备方法和应用
WO1991004341A1 (en) Hdv-specific peptides
JPH0694707A (ja) 診断方法
WO2004074516A2 (ja) モノクローナル抗体製剤の奏効性を向上させる方法
DK161098B (da) Antistoffer mod modificeret beta2-mikroglobulin, fremgangsmaader til detektering af modificeret beta2-mikroglobulin samt farmaceutiske praeparater indeholdende saadanne antistoffer

Legal Events

Date Code Title Description
MA Patent expired